Outlive
LongevityResearchHub
Promising — 51/100 Review / Commentary YouTube

Beta-2-Microglobulin and Neurogenesis: What's My Data?

Beta-2-Microglobulin Is Bad For Neurogenesis: What's My Data? (6-Test Analysis)

Mike Lustgarten February 15, 2026 Mike Lustgarten
TL;DR

Mike Lustgarten analyzes beta-2-microglobulin (B2M), a biomarker included in the Grimage epigenetic clock, exploring its role as a pro-aging factor that impairs neurogenesis in mice and is elevated in Alzheimer's disease brains. He presents his personal B2M measurements from 2025 and discusses dietary correlations he's tracking to optimize this biomarker.

Why This Matters

Mike Lustgarten analyzes beta-2-microglobulin (B2M), a biomarker included in the Grimage epigenetic clock, exploring its role as a pro-aging factor that impairs neurogenesis in mice and is elevated in Alzheimer's disease brains.

Credibility Assessment Promising — 51/100
Study Design
Rigor of the research methodology
11/20
Sample Size
Whether the study was sufficiently powered
9/20
Peer Review
Review status and journal reputation
11/20
Replication
Has this finding been independently reproduced?
8/20
Transparency
Funding disclosure and data availability
12/20
Overall
Sum of all five dimensions
51/100

What this means

Beta-2-microglobulin shows promise as a biomarker linked to brain health and aging, with solid mouse studies and intriguing human associations, but human causality remains unproven. Lustgarten's personal tracking is methodologically thoughtful but currently too preliminary to draw firm conclusions about optimal levels or dietary interventions.

Red Flags: YouTube video — not peer-reviewed research. 1) Commercial motivation: Core findings about optimal B2M are gated behind a Patreon subscription, creating financial incentive to emphasize B2M's importance. 2) Extrapolation from mice: The mechanistic studies are in mice; causal effects in humans remain speculative. 3) Preliminary personal data: Six tests over one year is insufficient to establish robust dietary correlations or resistance to age-related change; Lustgarten acknowledges this but still presents it prominently. 4) Postmortem Alzheimer's data: Association with disease does not establish causality or optimal thresholds. 5) Missing context: The transcript lacks discussion of B2M's primary known role (kidney function) and whether kidney function changes drive the neurogenesis findings. 6) Overstated confidence: The framing 'B2M is bad for neurogenesis' in the title is stronger than the evidence warrants—it's true in mice and correlates with Alzheimer's in humans, but causality in living humans is unproven.

This video focuses on beta-2-microglobulin (B2M), one of seven protein biomarkers in the Grimage epigenetic clock for mortality risk prediction. Lustgarten reviews published literature identifying B2M as a systemic pro-aging factor, then presents personal biomarker data and self-experimentation. The core scientific claims derive from peer-reviewed studies: a mouse study showing 12 days of B2M exposure reduced neurogenesis markers (doublecortin+ cells) by ~20%, and a B2M knockout study in 18-month-old mice showing 2x higher neurogenesis markers. Supporting evidence includes a postmortem brain study showing Alzheimer's disease patients had 2x higher B2M levels than controls.

Lustgarten presents his own data: six B2M tests from 2025 showing an average of 1.58 mg/L. He acknowledges this is "not terribly high" but aims to lower it further. His approach combines rigorous self-tracking—weighing 99%+ of food since 2015 via Chronometer—with blood biomarker testing to identify dietary correlations. He frames this as a longitudinal n-of-1 experiment, noting he needs at least three data points before statistical correlations become meaningful.

The video appropriately distinguishes between mouse mechanistic studies (strong evidence for B2M's role in neurogenesis) and human observational data (association between elevated B2M and Alzheimer's disease, but no causal proof). Lustgarten acknowledges uncertainty about whether B2M elevation in aging directly causes impaired neurogenesis in humans. He promotes a Patreon tier offering interpretations of optimal biomarker ranges based on aging trajectories and mortality associations, though the specific optimal B2M range is withheld from the free video.

Limitations include reliance on mouse models for mechanistic claims (which may not translate to humans), postmortem Alzheimer's data (correlative, not causal), and preliminary personal data (only one year of self-tracking). The dietary correlation analysis, while methodologically sound in principle, requires many more data points to yield reliable findings. Lustgarten's commercial interest in the Patreon tier is disclosed but represents a potential conflict regarding which claims he prioritizes.

Biomarkers of Aging Blood Biomarkers Epigenetic Age Epigenetic Clocks Epigenetics
View Original Source

0 Comments